Abstract
NO-sensitive guanylyl cyclase (NO-GC) acts as the receptor for nitric oxide and by the increase in cGMP executes most of the NO effects in the cardiovascular and neuronal system. Two isoforms of NO-GC exist whose existence has not been paid much attention to probably because they reveal comparable regulatory and catalytic properties and therefore cannot be differentiated in vivo. Analysis of mice in which either one of the isoforms has been genetically deleted unequivocally establishes the coexpression of NO-GC1 and NOGC2 in any tissue tested to date with the exception of platelets. In tissues other than brain and platelets, no particular function could be ascribed to a specific NO-GC isoform so far. In contrast, NO-GC1 and NO-GC2 serve different functions in the central nervous system. With NO-GC1's presynaptic role and NO-GC2's postsynaptic action, two NO/cGMP pathways have been shown to exist that enhance the strength of synaptic transmission on either side of the synaptic cleft.
Keywords: Nitric oxide, cGMP, guanylyl cyclase, knock-out, smooth muscle tone, blood pressure, inhibition of platelet aggregation, synaptic transmission.
Current Medicinal Chemistry
Title:Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Volume: 23 Issue: 24
Author(s): Doris Koesling, Evanthia Mergia and Michael Russwurm
Affiliation:
Keywords: Nitric oxide, cGMP, guanylyl cyclase, knock-out, smooth muscle tone, blood pressure, inhibition of platelet aggregation, synaptic transmission.
Abstract: NO-sensitive guanylyl cyclase (NO-GC) acts as the receptor for nitric oxide and by the increase in cGMP executes most of the NO effects in the cardiovascular and neuronal system. Two isoforms of NO-GC exist whose existence has not been paid much attention to probably because they reveal comparable regulatory and catalytic properties and therefore cannot be differentiated in vivo. Analysis of mice in which either one of the isoforms has been genetically deleted unequivocally establishes the coexpression of NO-GC1 and NOGC2 in any tissue tested to date with the exception of platelets. In tissues other than brain and platelets, no particular function could be ascribed to a specific NO-GC isoform so far. In contrast, NO-GC1 and NO-GC2 serve different functions in the central nervous system. With NO-GC1's presynaptic role and NO-GC2's postsynaptic action, two NO/cGMP pathways have been shown to exist that enhance the strength of synaptic transmission on either side of the synaptic cleft.
Export Options
About this article
Cite this article as:
Koesling Doris, Mergia Evanthia and Russwurm Michael, Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms, Current Medicinal Chemistry 2016; 23 (24) . https://dx.doi.org/10.2174/0929867323666160812145050
DOI https://dx.doi.org/10.2174/0929867323666160812145050 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Analgesia in PACU: Nonsteroidal Anti-Inflammatory Drugs
Current Drug Targets Editorial: Lipoprotein (a), More than Just Cholesterol?
Current Medicinal Chemistry Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Pindolol Augmentation of Antidepressant Response
Current Drug Targets Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Potential of High Mobility Group Box-1 in Ischemic Injury and Tissue Regeneration
Current Vascular Pharmacology Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Lipoprotein Lipase and Atherosclerosis
Current Vascular Pharmacology Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options
Current Rheumatology Reviews Plasma Protein Binding in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design